Convalescent Plasma in COVID-19

Authors

Ranjit S. Banwait, UCF/HCAFollow
Joshua K. Salabei, UCF/HCAFollow
Troy J. Fishman, UCF/HCAFollow
Uma G. Iyer, UCF/HCAFollow

Keywords

SARS-CoV-2; COVID-19; Coronavirus; passive immunization; COVID-19 serotherapy; intravenous immunoglobulins; plasma; emerging communicable diseases

Disciplines

Allergy and Immunology | Hematology | Infectious Disease | Medical Immunology | Medical Microbiology | Respiratory Tract Diseases | Virus Diseases

Abstract

The recent pandemic of SARS-CoV-2, which causes novel coronavirus disease 2019 (Covid-19), has had devastating impact on a global and national scale. In order to overcome this outbreak it is imperative we find treatments that are safe and effective. To date, no definitive treatment is available that can curtail the spread of this viral syndrome. Convalescent plasma (CP) is one such option that has repeatedly served as an important tool in treatment of various bacterial and viral infections, especially in the setting of no specific antimicrobial or vaccination against an infectious disease. Herein, we review the history of CP, prior usage of CP in various infections and pandemics to date, mechanism of action of the same and conclude with a brief overview of the experience gained so far with use of CP in COVID-19.

Recommended Citation

Banwait, Ranjit S.; Salabei, Joshua K.; Fishman, Troy J.; and Iyer, Uma G. (2020) "Convalescent Plasma in COVID-19," HCA Healthcare Journal of Medicine: Vol. 1: Iss. 3, Article 5.
DOI: 10.36518/2689-0216.1097
Available at: https://scholarlycommons.hcahealthcare.com/hcahealthcarejournal/vol1/iss3/5